John Ryan, MD

All posts by John Ryan, MD

February 13th, 2014

Fellows: Want to Blog for CardioExchange at ACC.14?


CardioExchange is looking for fellows to blog at ACC.14 in Washington, DC next month.

January 31st, 2014

A (Not So) New Drug Landscape for Pulmonary Arterial Hypertension

John Ryan offers a primer on three newly approved drugs for pulmonary arterial hypertension.

January 22nd, 2014

Prevention Guidelines in Practice: Vignette 1

A 71-year-old man asks John Ryan about reducing or stopping his hypertension medication

November 27th, 2013

Reflections on JFK From an Irish Cardiologist in Dallas

While attending AHA in Dallas, John Ryan visits the site of JFK’s assassination and reflects on what the President meant to the Irish then and now.

November 17th, 2013

What Council Involvement Can Add

The Associate Editor of CardioExchange explains the myriad benefits of AHA council involvement.

November 11th, 2013

Case: An Ironman with a Proximal Circumflex Lesion

, and

A 48-year-old man who runs 4 to 6 Ironman races per year reports non-exertional chest pain and is referred for a stress echocardiogram. His two sisters suffered MIs and died in their fifties, and his brother underwent CABG at age 49. The patient goes for 17 minutes on the Bruce stress protocol, with lateral and anterolateral wall […]

October 3rd, 2013

Fellows: Want to Blog for CardioExchange at AHA.13?


CardioExchange editors Harlan Krumholz and John Ryan are looking for fellows to blog for CardioExchange at the American Heart Association Annual Scientific Sessions from November 16th through the 20th in Dallas. If you are interested in blogging, please contact us. We look forward to hearing from you!

September 13th, 2013

Entering New Territory with the Subcutaneous ICD


John Ryan poses questions to Martin Burke, the lead investigator of the pivotal trial for the subcutaneous ICD (S-ICD).

September 12th, 2013

Aspirin Therapy with Anticoagulation in Patients with Afib?


An interview with Benjamin Steinberg about an analysis of data from the ORBIT-AF registry, in which patients with atrial fibrillation who were taking oral anticoagulation and aspirin had a higher risk of bleeding than patients on anticoagulation only.

September 11th, 2013

A New Standard For Pulmonary Hypertension Trials

Recently the New England Journal of Medicine published the SERAPHIN trial studying the effects of macitentan, a new endothelin receptor antagonist, in pulmonary arterial hypertension (PAH). This was a well-conducted study in 742 patients with PAH randomized to placebo, a low dose of macitentan (3mg once a day) and a high dose of macitentan (10mg once […]